Article

Tecnis multifocal safe and effective in hyperopia and presbyopia

The Tecnis multifocal intraocular lens (MIOL) is safe and efficacious for refractive lensectomy in hyperopia and presbyopia, according to Frank Goes, Belgium.

The Tecnis multifocal intraocular lens (MIOL) is safe and efficacious for refractive lensectomy in hyperopia and presbyopia, according to Frank Goes, Belgium.

At a private outpatient centre in Antwerp, Belgium, 94 presbyopic hyperopic eyes of 47 subjects were implanted with the Tecnis MIOL. Outcomes were recorded at six months from baseline.

The lens demonstrated two clearly defined focal points and MTF results, independent of pupil size. Uncorrected visual acuity (UCVA) improved from 20/100 preoperatively to 20/23 postoperatively. Best corrected visual acuity (BCVA) improved from 20/25 to 20/20. All but four eyes could read J1 monocular with eventual distance correction and 44 out of the 47 subjects could read J3 at intermediate PC distance (22 inches) with eventual distance correction. No eyes lost any lines of vision and 44 subjects were completely spectacle free. A questionnaire found that the satisfaction degree was either excellent (39 patients; 83%) or good (8 patients; 17%).

Goes concluded that the Tecnis lens is able to offer good visual performance, independent of pupil size, as well as being both safe and efficient in this patient population.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.